Use of hCG in controlled ovarian hyperstimulation
View Patent ↗The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG, or a bio-analogue, is administered during the follicular phase.
1. A method for aiding implantation and/or decreasing miscarriage rates, comprising administering to a patient in need thereof one or more low doses of human chorionic gonadotropin (hCG), or an analogue thereof, during controlled ovarian hyperstimulation (COH) in human patients but before ovulation or ovulation triggering, wherein the hCG or an analogue thereof is administered starting between the 3rd and 10th day after commencing treatment with FSH, an analogue thereof, or a compound that stimulates endogenous FSH secretion.
2. The method according to claim 1 , wherein the hCG or analogue thereof is administered starting before the 9 th day after commencing treatment with FSH, an analogue thereof, or a compound that stimulates endogenous FSH secretion.
3. The method according to claim 1 , wherein the hCG or analogue thereof is administered starting on or about the 7 th or 8 th day after commencing treatment with FSH, an analogue thereof, or a compound that stimulates endogenous FSH secretion.
4. The method according to claim 1 , wherein the hCG or an analogue thereof is administered at a dosage of 25-1000 IU hCG/day.
5. The method according to claim 1 , wherein the hCG or analogue thereof is administered at a dosage of 50-100 IU hCG/day.
6. The method according to claim 1 , wherein the hCG or analogue thereof is administered as a single bolus.
7. The method according to claim 6 , wherein the single bolus is administered on or about the 7 th or 8 th day after commencing treatment with FSH, an analogue thereof, or a compound that stimulates endogenous FSH secretion, and the bolus comprises 100-500 IU hCG.
8. The method according to claim 1 , wherein the hCG or analogue thereof is administered on a daily basis until ovulation is induced.
9. The method according to claim 1 , wherein the COH is carried out in conjunction with in vitro fertilization or in vivo fertilization.
10. The method according to claim 1 , wherein the patient suffers from low endogenous LH levels.
11. The method according to claim 1 , wherein the patient has previously exhibited failure to become or remain pregnant using COH alone.
12. The method according to claim 1 , wherein the hCG is recombinant hCG.
13. The method according to any one of claims 1 to 11 , wherein the hCG is urinary hCG.
14. The method according to claim 1 , wherein an analogue of hCG is used and wherein said analogue is a single chain hCG.
15. The method according to claim 1 , wherein an analogue of FSH is used and wherein said analogue is FSH-CTP, or wherein a compound that stimulates endogenous FSH secretion is used and said compound is an aromatase inhibitor, or clomiphene citrate.